Search research articles
Contact Us
Filters
Showing results (61-70 of 172) with videos related to
Page
of 18
Sort By:
Molecular Cancer Therapeutics
|
November 28, 2023
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma
Cha Len Lee, Grainne M O'Kane, Warren P Mason, et al.
European Urology Oncology
|
July 7, 2019
Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours
Peter Chung, Martin E O'Malley, Michael A S Jewett, et al.
Clinical Genitourinary Cancer
|
March 26, 2022
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets
Coralea Kappel, Di Maria Jiang, Bryan Wong, et al.
F1000Research
|
December 10, 2020
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
Milena Music, Marco Iafolla, Antoninus Soosaipillai, et al.
Cancer Research Communications
|
February 10, 2025
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, et al.
Clinical Colorectal Cancer
|
August 21, 2021
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
Kanan Alshammari, Kyaw L Aung, Tong Zhang, et al.
The Oncologist
|
April 7, 2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aaron R Hansen, Ian F Tannock, Arnoud Templeton, et al.
Epigenomics
|
September 2, 2020
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment
Madonna R Peter, Misha Bilenky, Ruth Isserlin, et al.
Clinical Genitourinary Cancer
|
March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Emerson A Lim, Michael T Schweizer, Kim N Chi, et al.
British Journal of Cancer
|
July 7, 2023
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
Helena J Janse van Rensburg, Zhihui Liu, Geoffrey A Watson, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 172) with videos related to
Sort By:
Page
of 18
Molecular Cancer Therapeutics
|
November 28, 2023
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma
Cha Len Lee, Grainne M O'Kane, Warren P Mason, et al.
European Urology Oncology
|
July 7, 2019
Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours
Peter Chung, Martin E O'Malley, Michael A S Jewett, et al.
Clinical Genitourinary Cancer
|
March 26, 2022
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets
Coralea Kappel, Di Maria Jiang, Bryan Wong, et al.
F1000Research
|
December 10, 2020
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
Milena Music, Marco Iafolla, Antoninus Soosaipillai, et al.
Cancer Research Communications
|
February 10, 2025
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, et al.
Clinical Colorectal Cancer
|
August 21, 2021
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer
Kanan Alshammari, Kyaw L Aung, Tong Zhang, et al.
The Oncologist
|
April 7, 2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aaron R Hansen, Ian F Tannock, Arnoud Templeton, et al.
Epigenomics
|
September 2, 2020
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment
Madonna R Peter, Misha Bilenky, Ruth Isserlin, et al.
Clinical Genitourinary Cancer
|
March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Emerson A Lim, Michael T Schweizer, Kim N Chi, et al.
British Journal of Cancer
|
July 7, 2023
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
Helena J Janse van Rensburg, Zhihui Liu, Geoffrey A Watson, et al.
Page
of 18